


Six common COVID myths busted by a virologist and a public health expert

November 29 2022, by Simon Nicholas Williams and Stephen Griffin



Credit: AI-generated image (disclaimer)

Almost three years into the pandemic, myths and misinformation remain widespread. Here we, a virologist and a public health researcher, debunk some common misconceptions about COVID.

Myth 1: The virus is becoming milder



There's a <u>prevailing myth</u> in the omicron era that <u>SARS-CoV-2</u> (the virus that causes COVID-19) is becoming "<u>milder</u>."

It's true that earlier omicron variants (BA.1 and BA.2) were <u>less likely</u> than delta to cause severe illness, partly because they were more likely <u>to infect the upper airway</u> than the lower airway. This means omicron infections didn't infect the lungs as aggressively as delta did.

But disease outcomes are critically dependent <u>on immunity</u> and the UK is <u>privileged in this regard</u>. When BA.2 hit Hong Kong in spring 2022, <u>poorer vaccination coverage</u> meant a <u>devastating outbreak</u>.

Even in England's well-vaccinated population there have been <u>almost</u> <u>29,000 COVID deaths</u> between January and early November 2022, and <u>tens of thousands</u> of hospitalizations.

Individual risk may have fallen, but high omicron infections and reinfections have considerable impact at population level. Subvariants continue to <u>escape antibody immunity</u>, and some (like BA.5) appear to have reacquired a <u>preference for the lower airway</u>. This, along with other factors, <u>increased the risk of hospitalization</u> with BA.5 compared to BA.2.

So SARS-CoV-2 is not inherently mild, or necessarily becoming milder. We must also remember that <u>millions of people</u> can't respond effectively to vaccines or are at heightened risk. Effective public health should combine updated vaccines against this moving target <u>with limiting infections</u> to <u>slow viral evolution</u>.

Myth 2: COVID only affects older and vulnerable people



One common reason people don't get vaccinated is <u>perceiving a low</u> <u>personal risk</u> from infection. Again, high prevalence inflates smaller individual risks. For <u>younger people</u>, even a mild infection can lead to long COVID, which affects <u>up to one in five adults</u> aged 18-64.

This myth is particularly problematic in relation to children. Kids are far less prone to severe COVID than adults, but among pediatric infectious diseases, COVID is a significant cause of <u>death</u> and <u>illness</u>. Children can also <u>develop long COVID</u>. Despite lackluster UK government messaging, many healthcare agencies around the world <u>recommend</u> vaccinating kids against SARS-CoV-2.

Myth 3: Washing hands is enough to prevent COVID spread

SARS-CoV-2 spreads via <u>tiny particles</u> of moisture suspended in the air called aerosols. Droplets (for example from sneezing) and fomites (droplet-contaminated objects) play a role, but are not the major route of spread.

As such, <u>ventilation</u> and <u>masks</u> are key to reducing COVID transmission. But hand washing and sanitizing have been more popular <u>anti-COVID</u> <u>measures</u>.

Some organizations were <u>slow to accept airborne transmission</u>. So messaging at the start of the pandemic, including from the UK government, over-emphasized the importance <u>of hand washing</u>.

A psychological phenomenon known as a "primacy effect" describes when people are more influenced by the first things they experience, and retain these concepts. It appears the early focus on <u>droplets and fomites</u> stuck in people's minds, even once we knew <u>SARS-CoV-2 was airborne</u>.



Hand hygiene is important for reducing transmission of other diseases, but is not sufficient for airborne viruses.

Myth 4: Masks don't work

Face masks work by protecting the wearer and others. But as with all mitigation strategies, this is never 100%. Masks work best alongside other measures and must be worn properly.

Masks range from cloth face coverings, to <u>surgical masks</u>, up to FFP2/N95 and FFP3/N99 respirators. Any barrier helps, but cloth masks mainly limit droplets and <u>do little</u> to protect the wearer from aerosols. <u>Surgical masks</u> with non-woven layers are significantly better, yet still offer limited protection compared with <u>respirators</u>.

Worn properly, FFP2 and FFP3 respirators filter <u>95% and 99%</u> of particles respectively, down to the size of aerosols. In this way they <u>protect the wearer and others</u>.

Myth 5: Vaccines don't reduce transmission

Delta caused noticeable <u>breakthrough infections</u> in people who had been vaccinated and reinfection is now <u>common with omicron</u>. This is due to the evolution of antibody-evasive mutations within SARS-CoV-2's spike protein, along with natural antibody waning.

Research <u>consistently supports</u> that vaccination reduces omicron transmission as well as severity. Studies show that, while not eliminating the risk entirely, vaccinated people with breakthrough infections are <u>less likely</u> to spread the virus to others.

Myth 6: Vaccines were rushed through



COVID <u>vaccine</u> trials were not rushed. Remarkable cooperation, ample funding and innovative design accelerated things. But what's usually the greatest bottleneck—patient recruitment—was bypassed by the sheer abundance of people exposed to SARS-CoV-2.

Vaccines saved an estimated <u>20 million lives globally</u> in 2021. But as effective as they are, vaccines, like all medicines, are not perfect.

Up to October 2022, the UK's Office for National Statistics <u>recorded 56</u> <u>deaths</u> in England and Wales involving COVID vaccines. All these deaths are tragedies. Patient reporting systems like the Medicines and Healthcare products Regulatory Agency <u>yellow card scheme</u> show higher numbers before investigations.

When <u>millions of people</u> are vaccinated, serious and potentially fatal reactions do occur on rare occasions. This is partly due to our genetic diversity, but other factors also contribute.

Rare reactions include <u>anaphylaxis</u> (allergic responses to vaccine ingredients), <u>blood clots</u> and myocarditis and pericarditis (inflammation of the heart muscle or surrounding sac).

It became clear after millions of inoculations that the AstraZeneca vaccine could <u>cause rare blood clots</u> in the veins. Untreated, this can be fatal. These occur more in younger adults, but the UK now uses mainly mRNA vaccines.

Myocarditis after mRNA vaccination has caused concern, mainly in adolescent males, but is generally rare, mild, and gets better on its own. By contrast, myocarditis from a COVID infection is more common, long-lasting, and far more likely to require intensive care. In other words, the benefits of COVID vaccination clearly outweigh the risks.



This article is republished from <u>The Conversation</u> under a Creative Commons license. Read the <u>original article</u>.

Provided by The Conversation

Citation: Six common COVID myths busted by a virologist and a public health expert (2022, November 29) retrieved 20 April 2024 from https://medicalxpress.com/news/2022-11-common-covid-myths-virologist-health.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.